Indicators of quality of life, anxiety-depressive symptoms and severity of dysmenorrhea in adolescent girls with peritoneal endometriosis during conservative therapy for a year

Khashchenko E.P. Khashchenko, М. Н. Алексеева, E.V. Uvarovа, Anastasiya Sivirinova, I.A. Salnikovа, S.O. Kyurdzidi
In: Meditsinskiy sovet = Medical Council · 2023 · pp. 72–81 · doi:10.21518/ms2023-345 · W4387876780
article OA: diamond CC0
🔓 Open OA copy Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

One year of conservative therapy for adolescent peritoneal endometriosis significantly reduced pain, anxiety, and depression while improving quality of life, with estradiol levels correlating with affective disorder symptoms.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 · read from full text ⓘ

This prospective longitudinal study followed 45 adolescent girls (ages 13–17) with confirmed peritoneal endometriosis, assessing dysmenorrhea and chronic pelvic pain, anxiety-depressive symptoms, and quality of life before and after 1 year of conservative therapy (continuous dienogest plus NSAIDs and drotaverine for pain relief). After treatment, girls showed statistically significant reductions in dysmenorrhea, chronic pelvic pain, gastrointestinal and urinary symptoms, activity and work limitations, as well as lower scores for depressive and anxiety symptoms across BDI, HADS, and STAI, alongside improved SF-36 physical and psychological components (all p < 0.001). The authors also report a tendency toward reduced hormonal and inflammatory blood parameters within reference ranges and identify estradiol level as a factor associated with higher affective symptom scores (STAI reactivity, HADS anxiety and depression). This paper does not explicitly state a key limitation in the provided text, but it is observational over a single follow-up period and uses composite outcomes measured by questionnaires and blood markers. This paper is centrally about endometriosis — it evaluates quality of life, anxiety/depression symptoms, and dysmenorrhea severity in adolescents with peritoneal endometriosis undergoing 1 year of conservative therapy.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Introduction . Delayed diagnosis and treatment of endometriosis lead to impaired quality of life and pain chronification in young female patients. Aim . To study indicators of quality of life, anxiety, depression and pain syndrome in adolescents with peritoneal endometriosis (PE) over a one-year period of conservative therapy. Materials and methods . A total of 45 girls aged 13 to 17 years with a confirmed diagnosis of PE were enrolled in a prospective longitudinal study. Pain syndrome (VAS, McGill Pain Questionnaire), anxiety-depressive symptoms (Beck Depression Inventory (BDI), Hospital Anxiety and Depression Scale (HADS), Spielberger State-Trait Anxiety Inventory (STAI)), quality of life indicators (SF-36) were assessed before and after one year of treatment in female patients (dienogest administered continuously, NSAIDs and drotaverine for immediate pain relief only). Results . One year of therapy resulted in a significant decrease in the severity of dysmenorrhea and chronic pelvic pain, gastrointestinal symptoms and dysuria, daily activity and productivity impairment (p < 0.001) in girls with PE. In addition, the study demonstrated decreased indicators of anxiety and depressive disorders (BDI depression, HADS anxiety and depression, STAI reactive and personal anxiety (p < 0.001)) and an improvement in quality-of-life indicators (physical and psychological component, average index (p < 0.001)). There was a declining trend in blood hormone and inflammation test results within the reference range during treatment. The estradiol level has been shown to be a risk factor for high levels of affective disorder symptoms in adolescents with PE: STAI reactive anxiety (p = 0.046), HADS anxiety and depression (p = 0.044 and 0.033, respectively). Conclusion . The one-year therapy of PE in adolescents (dienogest administered continuously, a combination of NSAIDs and drotaverine in pain syndrome only) was associated with significantly improved quality of life, decreased severity of anxietydepressive disorders and pain, which confirms the need to start therapy when symptoms of the disease begin to show them-selves in adolescence.
Full text 10,142 characters · extracted from oa-html · click to expand
Показатели качества жизни, тревожно-депрессивной симптоматики и выраженности дисменореи у девочек-подростков с перитонеальным эндометриозом на фоне консервативной терапии в течение года https://doi.org/10.21518/ms2023-345 Аннотация Введение. Несвоевременная диагностика и лечение эндометриоза приводят к снижению качества жизни и хронизации болевого синдрома у молодых пациенток. Цель. Изучить показатели качества жизни, тревожности, депрессии и болевого синдрома у подростков с перитонеальным эндометриозом (ПЭ) на фоне консервативной терапии в течение 1 года. Материалы и методы. В проспективное продольное исследование включены 45 девочек от 13 до 17 лет с подтвержденным диагнозом ПЭ. Оценка болевого синдрома (ВАШ, опросник боли Мак-Гилла), тревожно-депрессивных симптомов (шкала депрессии Бека (BDI), госпитальная шкала тревоги и депрессии (HADS), опросник Спилбергера (STAI)), показателей качества жизни (SF-36) произведена до и после 1 года лечения пациенток (диеногест в непрерывном режиме, НПВС и дротаверин с целью купирования болевого синдрома). Результаты. Через 1 год на фоне терапии у девочек с ПЭ значимо снизилась выраженность дисменореи и хронической тазовой боли, гастроинтестинальных симптомов и дизурии, ограничения повседневной активности и работоспособности (p < 0,001). Кроме того, отмечено снижение показателей тревожно-депрессивных расстройств (BDI депрессии, HADS тревоги и депрессии, STAI реактивной и личностной тревожности (p < 0,001)) и улучшение показателей качества жизни (физический и психологический компонент, средний индекс (p < 0,001)). Отмечена тенденция к снижению гормональных и воспалительных параметров крови на фоне лечения в пределах референсных интервалов. Показано, что уровень эстрадиола является фактором высоких значений аффективной симптоматики у подростков с ПЭ: реактивная тревожность STAI (p = 0,046), тревога и депрессия по шкале HADS (p = 0,044 и 0,033 соответственно). Заключение. Терапия ПЭ у подростков в течение 1 года (диеногест непрерывно, комбинация НПВС с дротаверином при болевом синдроме) была ассоциирована со значимым улучшением качества жизни, снижением выраженности тревожно-депрессивных расстройств и болевого синдрома, что подтверждает необходимость начала терапии с момента манифестации заболевания в подростковом возрасте. Ключевые слова Об авторах Е. П. ХащенкоРоссия Хащенко Елена Петровна – кандидат медицинских наук, ведущий научный сотрудник 2-го гинекологического отделения (гинекологии детского и юношеского возраста). 117997, Москва, ул. Академика Опарина, д. 4 М. Н. Алексеева Россия Алексеева Мария Николаевна - студент факультета фундаментальной медицины. 119234, Москва, ул. Колмогорова, д. 1 Е. В. Уварова Россия Уварова Елена Витальевна - член-корреспондент РАН, доктор медицинских наук, профессор, заведующий 2-м гинекологическим отделением (гинекологии детского и юношеского возраста), НМИЦ АГП им. ак. В.И. Кулакова; профессор кафедры акушерства, гинекологии, перинатологии и репродуктологии Института профессионального образования, ПМГМУ им. И.М. Сеченова (Сеченовский Университет). 117997, Москва, ул. Академика Опарина, д. 4; 119991, Москва, ул. Трубецкая, д. 8, стр. 2 А. С. Сивиринова Россия Сивиринова Анастасия Сергеевна - аспирант факультета фундаментальной медицины. 119234, Москва, ул. Колмогорова, д. 1 С. А. Сальникова Россия Сальникова Ирина Александровна - научный сотрудник 2-го гинекологического отделения. 117997, Москва, ул. Академика Опарина, д. 4 С. О. Кюрдзиди Россия Кюрдзиди Станислав Олегович - аспирант кафедры акушерства, гинекологии, перинатологии и репродуктологии Института профессионального образования. 119991, Москва, ул. Трубецкая, д. 8, стр. 2 Список литературы 1. Schneider MP, Vitonis AF, Fadayomi AB, Charlton BM, Missmer SA, DiVasta AD. Quality of Life in Adolescent and Young Adult Women With Dyspareunia and Endometriosis. J Adolesc Health. 2020;67(4):557–561. https://doi.org/10.1016/j.jadohealth.2020.02.024. 2. Mińko A, Turoń-Skrzypińska A, Rył A, Bargiel P, Hilicka Z, Michalczyk K et al. Endometriosis-A Multifaceted Problem of a Modern Woman. Int J Environ Res Public Health. 2021;18(15):8177. https://doi.org/10.3390/ijerph18158177. 3. Ball E, Khan KS. Recent advances in understanding and managing chronic pelvic pain in women with special consideration to endometriosis. F1000Res. 2020;9:83. https://doi.org/10.12688/f1000research.20750.1. 4. Quiñones M, Urrutia R, Torres-Reverón A, Vincent K, Flores I. Anxiety, coping skills and hypothalamus-pituitary-adrenal (HPA) axis in patients with endometriosis. J Reprod Biol Health. 2015;3:2. https://doi.org/10.7243/2054-0841-3-2. 5. Friedl F, Riedl D, Fessler S, Wildt L, Walter M, Richter R et al. Impact of endometriosis on quality of life, anxiety, and depression: an Austrian perspective. Arch Gynecol Obstet. 2015;292(6):1393–1399. https://doi.org/10.1007/s00404-015-3789-8. 6. González-Echevarría AM, Rosario E, Acevedo S, Flores I. Impact of coping strategies on quality of life of adolescents and young women with endometriosis. J Psychosom Obstet Gynaecol. 2019;40(2):138–145. https://doi.org/10.1080/0167482X.2018.1450384. 7. Gallagher JS, DiVasta AD, Vitonis AF, Sarda V, Laufer MR, Missmer SA. The Impact of Endometriosis on Quality of Life in Adolescents. J Adolesc Health. 2018;63(6):766–772. https://doi.org/10.1016/j.jadohealth.2018.06.027. 8. DiVasta AD, Vitonis AF, Laufer MR, Missmer SA. Spectrum of symptoms in women diagnosed with endometriosis during adolescence vs adulthood. Am J Obstet Gynecol. 2018;218(3):324.e1–324.e11. https://doi.org/10.1016/j.ajog.2017.12.007. 9. Hirsch M, Dhillon-Smith R, Cutner AS, Yap M, Creighton SM. The Prevalence of Endometriosis in Adolescents with Pelvic Pain: A Systematic Review. J Pediatr Adolesc Gynecol. 2020;33(6):623–630. https://doi.org/10.1016/j.jpag.2020.07.011. 10. Sieberg CB, Lunde CE, Borsook D. Endometriosis and pain in the adolescent-striking early to limit suffering: A narrative review. Neurosci Biobehav Rev. 2020;108:866–876. https://doi.org/10.1016/j.neubiorev.2019.12.004. 11. Simpson CN, Lomiguen CM, Chin J. Combating Diagnostic Delay of Endometriosis in Adolescents via Educational Awareness: A Systematic Review. Cureus. 2021;13(5):e15143. https://doi.org/10.7759/cureus.15143. 12. Eisenberg VH, Decter DH, Chodick G, Shalev V, Weil C. Burden of Endometriosis: Infertility, Comorbidities, and Healthcare Resource Utilization. J Clin Med. 2022;11(4):1133. https://doi.org/10.3390/jcm11041133. 13. Ross V, Detterman C, Hallisey A. Myofascial Pelvic Pain: An Overlooked and Treatable Cause of Chronic Pelvic Pain. J Midwifery Womens Health. 2021;66(2):148–160. https://doi.org/10.1111/jmwh.13224. 14. Pastore EA, Katzman WB. Recognizing myofascial pelvic pain in the female patient with chronic pelvic pain. J Obstet Gynecol Neonatal Nurs. 2012;41(5):680–691. https://doi.org/10.1111/j.1552-6909.2012.01404.x. 15. Stratton P, Winkel CA, Sinaii N, Merino MJ, Zimmer C, Nieman LK. Location, color, size, depth, and volume may predict endometriosis in lesions resected at surgery. Fertil Steril. 2002;78(4):743–749. https://doi.org/10.1016/s0015-0282(02)03337-x. 16. Aredo JV, Heyrana KJ, Karp BI, Shah JP, Stratton P. Relating Chronic Pelvic Pain and Endometriosis to Signs of Sensitization and Myofascial Pain and Dysfunction. Semin Reprod Med. 2017;35(1):88–97. https://doi.org/10.1055/s-0036-1597123. 17. Missmer SA, Tu FF, Agarwal SK, Chapron C, Soliman AM, Chiuve S et al. Impact of Endometriosis on Life-Course Potential: A Narrative Review. Int J Gen Med. 2021;14:9–25. https://doi.org/10.2147/IJGM.S261139. 18. Aerts L, Grangier L, Streuli I, Dällenbach P, Marci R, Wenger JM, Pluchino N. Psychosocial impact of endometriosis: From co-morbidity to intervention. Best Pract Res Clin Obstet Gynaecol. 2018;50:2–10. https://doi.org/10.1016/j.bpobgyn.2018.01.008. 19. Koninckx PR, Fernandes R, Ussia A, Schindler L, Wattiez A, Al-Suwaidi S et al. Pathogenesis Based Diagnosis and Treatment of Endometriosis. Front Endocrinol (Lausanne). 2021;12:745548. https://doi.org/10.3389/fendo.2021.745548. 20. Shim JY, Laufer MR. Adolescent Endometriosis: An Update. J Pediatr Adolesc Gynecol. 2020;33(2):112–119. https://doi.org/10.1016/j.jpag.2019.11.011. 21. Becker CM, Bokor A, Heikinheimo O, Horne A, Jansen F, Kiesel L et al. ESHRE guideline: endometriosis. Hum Reprod Open. 2022;(2):hoac009. https://doi.org/10.1093/hropen/hoac009. 22. Patel BG, Lenk EE, Lebovic DI, Shu Y, Yu J, Taylor RN. Pathogenesis of endometriosis: Interaction between Endocrine and inflammatory pathways. Best Pract Res Clin Obstet Gynaecol. 2018;50:50–60. https://doi.org/10.1016/j.bpobgyn.2018.01.006. 23. Guimarães I, Póvoa AM. Primary Dysmenorrhea: Assessment and Treatment. Rev Bras Ginecol Obstet. 2020;42(8):501–507. https://doi.org/10.1055/s-0040-1712131. 24. Pareek A, Chandurkar NB, Patil RT, Agrawal SN, Uday RB, Tambe SG. Efficacy and safety of aceclofenac and drotaverine fixed-dose combination in the treatment of primary dysmenorrhoea: a double-blind, doubledummy, randomized comparative study with aceclofenac. Eur J Obstet Gynecol Reprod Biol. 2010;152(1):86–90. https://doi.org/10.1016/j.ejogrb.2010.05.007. 25. Patai Z, Guttman A, Mikus EG. Potential L-Type Voltage-Operated Calcium Channel Blocking Effect of Drotaverine on Functional Models. J Pharmacol Exp Ther. 2016;359(3):442–451. https://doi.org/10.1124/jpet.116.237271. Рецензия Для цитирования: Хащенко ЕП, Алексеева МН, Уварова ЕВ, Сивиринова АС, Сальникова СА, Кюрдзиди СО. Показатели качества жизни, тревожно-депрессивной симптоматики и выраженности дисменореи у девочек-подростков с перитонеальным эндометриозом на фоне консервативной терапии в течение года. Медицинский Совет. 2023;(15):72-81. https://doi.org/10.21518/ms2023-345 For citation: Khashchenko EP, Alekseeva MN, Uvarova EV, Sivirinova AS, Salnikova IA, Kyurdzidi SO. Indicators of quality of life, anxiety-depressive symptoms and severity of dysmenorrhea in adolescent girls with peritoneal endometriosis during conservative therapy for a year. Meditsinskiy sovet = Medical Council. 2023;(15):72-81. (In Russ.) https://doi.org/10.21518/ms2023-345 JATS XML

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Outcome instruments

VAS-pain

Condition tags

endometriosischronic_pelvic_paindysmenorrhea

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (25)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK